Skip to content

Ardelyx ARDX Available for sale investments

Available for sale investments at other companies

Amgen logo
AmgenAMGN
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's available for sale investments?
Ardelyx (ARDX) reported available for sale investments of $206.87M in Q1 2026.
How has Ardelyx's available for sale investments changed year-over-year?
Ardelyx's available for sale investments increased by 13.0% year-over-year, from $183.14M to $206.87M.
What is the long-term trend for Ardelyx's available for sale investments?
Over 5 years (2020 to 2025), Ardelyx's available for sale investments has grown at a 15.6% compound annual growth rate (CAGR), from $95.45M to $196.69M.